Amplitude Vascular's New Funding Round Shows Why the IVL Market Is Red HotAmplitude Vascular's New Funding Round Shows Why the IVL Market Is Red Hot
Amplitude Vascular Systems has raised $36 million to help fund the launch of its intravascular lithotripsy. The Boston, MA-based company is in a highly competitive market where Johnson & Johnson and Boston Scientific hold significant market share.
January 28, 2025
.png?width=1280&auto=webp&quality=95&format=jpg&disable=upscale)
A player in the intravascular lithotripsy (IVL) space has reached a significant milestone.
Amplitude Vascular Systems said it has closed on a series B round financing of $36 million. The Boston, MA-based company is using the funding to support the peripheral commercial launch as well as the coronary and carotid IDE trials for its Pulse Intravascular Lithotripsy (PIVL) device.
“We are pleased to see strong, sustained investor excitement around this technology,” said Mark Toland, board chairman for AVS. “Intravascular lithotripsy now represents a large and well-proven therapy that demands new solutions for patients with severely calcified arterial disease. This investor confidence reflects the accelerated execution of critical company milestones in 2024, including the initiation of our U.S. peripheral IDE. The commitment from our partners at BioStar Capital and Cue Growth Partners reinforces the great progress toward commercial approval with this technology in the IVL space.”
AVS began enrolling patients in October 2024 in the POWER PAD II U.S. IDE trial, which is a prospective, single-arm, multi-center study evaluating the technical and clinical success of the PULSE IVL System for treating patients with calcific femoropopliteal arteries. The study will enroll up to 120 patients at 20 U.S. sites and enrollment is expected to be completed mid-year 2025.
The funding will also support the company’s coronary U.S. IDE study.
Lastly, the capital raised will support the U.S. carotid IDE trial, as part of its partnership with the Jacobs Institute in Buffalo, NY.
Observing Big Moments in IVL Market
The IVL market is projected to have a compound annual growth rate of 9.3% from 2020 to 2030, according to a report from iData Research.
There has been significant movement in the space in recent months. Johnson & Johnson made medtech headlines when it acquired Shockwave Medical for %13.1 billion, an established heavyweight in IVL.
Not to be left behind, Boston Scientific acquired Bolt, the developer of the Bolt IVL system. The acquisitions put Johnson & Johnson and Boston Scientific in a showdown in the IVL market.
Even smaller players in the space have been making traction.
Earlier this month, FastWave Medical, a company developing a laser IVL technology, reported it was awarded its 7th patent.
About the Author
You May Also Like